Does Insurance Cover Hormone Pellets? What 11 Public Coverage Documents Say in 2026

Does insurance cover hormone pellets? For compounded pellets used for menopause, usually not. In 11 current public coverage documents, every commercial policy that directly addressed compounded menopause pellets excluded or restricted them; separate Testopel policies created only narrow, diagnosis-specific paths. The visit and labs may be decided separately, and your member contract controls. ^{[1][2][3][4][5][6][7][8]}

That's the short version. Here's the part almost nobody explains, and it's the part that actually changes what you do next: “hormone pellets” is not one bill. It can create five separate coverage decisions — the visit, the labs, the pellet itself, the insertion, and the follow-up. Some of those can be covered while the pellet is excluded.

We'll show you all five, the codes your clinic may submit, the public prices we found, and the four questions that get you a useful answer before you hand over a deposit.

What changes the answer?

Your result depends on the exact product, why it is being prescribed, your plan and state, network status, the codes submitted, and any authorization or benefit-exclusion rules. “Testopel,” “compounded estradiol pellet,” and “compounded testosterone pellet” are not interchangeable insurance questions.

This page is for you if

• You were quoted a cash price or asked for a deposit.
• A clinic told you insurance “never covers HRT for women.”
• Your claim or superbill came back denied.
• You're weighing pellets against a patch, pill, gel, spray, ring, or vaginal product.

This page is not for you if

• You're a man researching testosterone pellets. Testopel has labeled indications in males and different coverage criteria; use your plan's current testosterone policy.
• You're seeking gender-affirming hormone care. Some policies have separate benefit and diagnosis rules that deserve a specialist source and your current plan document.
• You already have an implant-site problem. Contact the clinician who inserted the pellets rather than using a coverage article as medical guidance.

The 60-second version

What you're asking about	Bottom line
Compounded pellet for menopause	The eight commercial documents reviewed did not create routine coverage; the policies that addressed this use excluded or restricted it.
Testopel	FDA-approved testosterone pellet with male labeled indications; some policies have narrow, diagnosis-specific coverage paths. It is not FDA-approved for menopausal symptoms.
The office visit	Check separately under your medical benefit and confirm both clinician and facility network status.
Your lab work	Check the exact tests, ordering clinician, laboratory, diagnosis, and whether the clinic package includes them.
The insertion procedure — CPT 11980	A valid billing code identifies a service. It does not prove that your plan covers the product, indication, or provider.
Your HSA or FSA	It may help when the expense meets qualified-medical-expense rules, but there is no pellet-specific IRS ruling. Confirm documentation with your administrator.
Public cash prices we found	Four clinic pages listed women's insertion prices from $300 to $500, with consults, labs, frequency, and follow-up changing the annual total.

→ Print the four questions to ask before you pay One focused phone call. No guesswork disguised as a coverage answer.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Does insurance cover hormone pellets? Here's what 11 public coverage documents say.

Across the eight commercial medical-policy documents in this review, every policy that directly addressed compounded menopause pellets excluded or restricted them. The separate Testopel policies created only narrow, diagnosis-specific paths. Medicaid and Medicare documents added authorization and jurisdiction rules, not a blanket menopause-pellet benefit. ^{[1][2][3][4][5][6][7][8][9][10][11]}

We didn't want to give you another article that says “it depends” and then abandons you. So we opened the documents, separated compounded pellets from Testopel, recorded the policy dates, and kept procedure coverage separate from product coverage.

The 2026 policy ledger

Read and compared by The HRT Index; last checked August 27, 2026.

Payer and document	Date or current status	What the document says	What it does not prove
Aetna — CPB 0345, Implantable Hormone Pellets	Last reviewed July 8, 2026	Implantable estradiol is experimental, investigational, or unproven; menopause-related testosterone-pellet use is listed among noncovered indications. Testopel has narrow criteria for qualifying hypogonadism, delayed male puberty, and certain gender-affirming-care criteria.	That every progesterone-pellet use is excluded under one blanket rule; Aetna's progesterone language is indication-specific. [1]
UnitedHealthcare — Testosterone Replacement or Supplementation Therapy	Effective January 1, 2026	Compounded testosterone, estrogen, and progesterone pellets are not proven or medically necessary for any indication under this policy. Testopel has separate, diagnosis-specific criteria.	That a code listing or authorization guarantees payment. [2]
Cigna — IP0251, Compounded Medications	Effective December 15, 2025	Compounded hormone pellets are experimental, investigational, or unproven. The policy associates CPT 11980 and several unclassified drug codes with compounded-pellet claims.	That every compounded claim uses the same drug code. [3]
Cigna — IP0351, Testosterone Injectable and Implant	Effective December 15, 2025	Testopel may meet criteria for specified testosterone-deficiency or gender-affirming indications; the policy recognizes CPT 11980 with J1073.	A routine menopause-pellet benefit for women. [4]
Blue Cross NC — Hormone Pellet Implantation for Treatment of Menopause-Related Symptoms	Maintained policy; update posted April 15, 2026	Estrogen alone, estrogen plus testosterone, or testosterone alone by pellet for menopause-related symptoms is investigational, and investigational services are not covered under the policy.	What a different Blue Cross plan in another state will do. [5]
Capital Blue Cross — Medical Policy 2.345	Effective January 1, 2026	Estradiol pellets and testosterone pellets for postmenopausal symptoms are investigational. Testopel has narrow criteria for other indications.	A national Blue Cross rule. [6]
Arkansas Blue Cross and Blue Shield — hormone-pellet policy	Last reviewed October 2025	Estrogen-containing pellets are not covered; Testopel has product- and diagnosis-specific criteria, and other uses are excluded or investigational. The policy names CPT 11980, J1073, J3490, and legacy S0189.	That the presence of those codes creates coverage. [7]
Blue Cross & Blue Shield of Mississippi — hormone pellet implantation for HRT in women	Reviewed July 15, 2026	Hormone pellet therapy in women is described as not medically necessary, with the administration service addressed alongside the product.	What another Blue plan or a self-funded employer contract covers. [8]
Humana Florida Medicaid — provider-administered drug prior-authorization list	Effective January 1, 2026; revised July 1, 2026	Testopel/J1073 appears on the prior-authorization list. The document says authorization is not a guarantee of payment.	Coverage for compounded menopause pellets or eligibility for a menopause diagnosis. [9]
CMS/Palmetto — LCD L39086	Active when checked August 27, 2026	The LCD addresses treatment of low testosterone in males within the listed Medicare jurisdiction.	A national menopause-pellet benefit for women. [10]
CMS/Palmetto — Article A58828	Active; revision effective April 2, 2026	The billing article supports the associated male-low-testosterone LCD and its documentation rules.	That a retired CMS article from another contractor still governs a current claim. [11]

What our review found

• Eight commercial documents: every document that directly addressed compounded menopause pellets excluded or restricted them; the separate Testopel documents limited coverage to narrow criteria.
• Two separate Cigna documents: one addresses compounded medication; the other addresses the FDA-approved testosterone implant. Keeping them separate changes the answer.
• One Medicaid PA list: Testopel appears, but the list itself warns that authorization does not guarantee payment.
• Two active CMS documents: both are tied to male low-testosterone coverage in a specific Medicare contractor jurisdiction, not a national menopause-pellet rule.

This is a purposive review of 11 public documents, not a national coverage rate. We are not going to tell you “87% of plans deny pellets” or “some patients get 80% back” without a representative dataset. Your employer's self-funded contract, your exact member certificate, network status, coding, deductible, and state rules can still change your result.

What “experimental,” “investigational,” or “unproven” means on a plan

It is not the insurer saying your hot flashes aren't real.

Those words are policy categories. They usually mean the plan evaluated a treatment class and decided the evidence did not meet its coverage standard. That matters because a medical-necessity appeal argues that your case meets criteria. A benefit exclusion or investigational classification may be a different fight entirely.

We'll come back to that in the appeals section, because the denial reason decides what you do next.

---

Why isn't “hormone pellets” one insurance bill?

One pellet appointment can create five separate coverage decisions: the consultation, laboratory work, pellet product, implantation, and follow-up or removal. They may run through different benefits and rules, so one line can be covered while another is excluded. Asking only “Are pellets covered?” collapses five questions into one and produces an answer you can't use.

Your clinic says, “We don't take insurance.” Your insurer says, “We cover hormone therapy.” Both can be true at once because they're talking about different line items.

The Five Coverage Decisions

Decision	What it covers	What to ask	Where it goes wrong
1. The consultation	The clinician visit	Is the clinician in-network? Is the facility separately in-network? Will the clinic submit a claim?	A clinic can be cash-only even when a prescription from another provider would use your benefits.
2. Laboratory work	Baseline and monitoring tests	Which exact tests? Which laboratory? Is it in-network? Are tests included in the package price?	“Pellets are cash-pay” says nothing about how an outside laboratory claim will be handled.
3. The pellet product	The implanted medication	What is the exact ingredient and strength? Is it Testopel or compounded? Who manufactured or compounded it? What code will be submitted?	“Bioidentical” does not identify a product, approval status, or benefit.
4. The insertion	The implantation service, often associated with CPT 11980	Will CPT 11980 be submitted? Is it payable with this product and diagnosis at this site of service?	A real code feels like proof of coverage. It isn't.
5. Follow-up or removal	Site checks, repeat labs, removal, and treatment of an implant-site problem	What is included? What would an extra visit or removal cost? Who handles complications?	Nobody asks this before insertion. Everybody wishes they had.

Ask about all five separately. Write down the answers.

That fifth row deserves a moment. Testopel's current label says implanted pellets are less flexible for dose adjustment than other routes and may need to be removed when treatment must be stopped. The label also reports implant-site infection and extrusion, often within the first month. That's not a scare tactic. It's a billing question: if a clinician needs to examine or remove something, who bills it and how? ^[12]

The four questions to ask before you pay

Print this. Take it to the front desk. Get the answers before the deposit becomes nonrefundable.

1. 1. “Will you submit claims to my insurance, or am I paying in full?” A straight answer names what the clinic bills, what it does not bill, and whether it supplies an itemized document for you.
2. 2. “What exact product and ingredients are you implanting?” A straight answer names Testopel or the compounded ingredients, strength, and pharmacy or manufacturer. If the answer is only “bioidentical,” ask again.
3. 3. “What codes and diagnosis will you submit?” Ask for the CPT, HCPCS or other drug code, diagnosis code, place of service, and provider or facility name. Do not choose the code yourself; the clinic supplies it.
4. 4. “Which visits and labs may go through insurance, and what is my full cash responsibility?” A straight answer separates the consult, outside lab, in-house tests, pellet, insertion, follow-up, and potential removal.

→ Save the printable four-question card

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

---

What can't this page tell you about your own plan?

We cannot tell you exactly what your plan will pay. No public article can. Your member contract, eligibility on the service date, network, authorization, coding, allowed amount, deductible, and claim processing decide the final number.

Here's the scenario that cuts against the simple “pellets are cash-pay” answer: a PPO can have out-of-network benefits, and a claim may be considered when the plan has no applicable pellet exclusion. That is not a promise of reimbursement. It is a reason to read the benefit and medical-policy language before assuming the answer is zero.

So here's the trade we're offering. We can't give you a fake personalized dollar amount. We can show you what the plan is likely evaluating, what the clinic must tell you, what current public policies say, and which covered routes are worth comparing. That is the information that changes what you do this week.

---

Why do insurers deny hormone pellets?

The denial is usually about the product, evidence category, benefit language, diagnosis, authorization, or network — not a claim that menopause treatment never works. Compounded drugs are not FDA-approved before marketing, and several current payer policies place compounded hormone pellets in experimental, investigational, unproven, or not-medically-necessary categories. ^{[13][1][2][3]}

There are five common reasons a pellet claim dies. Knowing which one you have saves hours of arguing the wrong point.

1. The product is compounded

Compounded drugs are prepared for an individual prescription outside the FDA's standard premarket approval process. They can fill a genuine clinical need when an FDA-approved product cannot meet a specific patient's needs, but the FDA does not review a compounded finished drug for safety, effectiveness, or manufacturing quality before it is marketed the way it reviews an approved product. Many plans stop right there. ^[13]

One thing we won't do here: tell you a compounded pellet is the same as, equivalent to, safer than, more natural than, or clinically interchangeable with an FDA-approved product. FDA guidance says compounded “bioidentical” hormones have not been shown safer or more effective than approved hormone therapies. The Menopause Society also separates “bioidentical” from “compounded” and says custom-compounded hormones have not been shown safer or more effective. ^[13][14]

2. The policy classifies it as experimental, investigational, or unproven

Aetna's reason is unusually specific: its bulletin says implantable estradiol pellets can produce “unpredictable and fluctuating” estrogen concentrations. UnitedHealthcare and Cigna use their own evidence standards and reach a similar coverage result for compounded pellets. ^[1][2][3]

In fairness, the pellet literature isn't empty. A 2025 critical review found published observational experience but concluded that evidence for compounded testosterone pellets in women remains limited and low quality. We are not trying to settle the clinical argument on an insurance page. We are showing you which evidence argument your plan is applying. ^[15]

3. The claim does not meet medical-necessity criteria

This one is about the records submitted: product, diagnosis, symptoms, laboratory documentation when required, prior treatment, contraindications, dose, and follow-up plan. Meeting criteria still does not override a benefit exclusion.

4. The service is excluded by the contract

This is contractual. The plan says it does not pay for the category. An appeal has less leverage here than it does when the issue is missing records or a coding mistake — though you should still confirm that the exclusion was applied to the right product and claim.

5. The clinician, facility, or laboratory is out-of-network

This is a separate decision. A service can be clinically eligible and still pay little or nothing because of who performed it, where it was performed, or which laboratory processed the tests.

What medical groups say — and why it shows up in payer policy

ACOG's current clinical consensus says compounded menopausal hormone therapy should not be prescribed routinely when FDA-approved options exist. For testosterone, ACOG recommends a route other than pellets because of limited safety data and the difficulty of removing an implanted dose. It also states that no testosterone formulation is FDA-approved for menopausal symptoms in women. ^[16]

The Menopause Society likewise says custom-compounded hormone products have not been shown safer or more effective than FDA-approved therapies. Those positions do not decide every woman's clinical care. They do help explain why payer policies draw a hard line around compounded pellets. For the separate clinical-risk question, see Are Hormone Pellets Safe?. ^[14]

The part most “not covered” answers miss

A plan can exclude a compounded pellet while covering a named FDA-approved menopause product. That does not mean your patch, pill, gel, spray, ring, or vaginal product is automatically covered; each has its own formulary position and restrictions. It means “insurance doesn't cover HRT for women” is the wrong sentence. The exact product and route are the sentence.

---

Are any hormone pellets FDA-approved?

Testopel is the FDA-approved testosterone pellet named in the payer policies reviewed. Its label is for testosterone replacement in males with specified forms of hypogonadism and for selected cases of delayed puberty; it is not FDA-approved for menopausal symptoms. We found no FDA-approved estradiol pellet, and the compounded pellets marketed to women are not FDA-approved finished drugs. ^[12][1][6]

Testopel is approved — for a different labeled use

Testopel contains 75 mg of testosterone per pellet. Its current label covers replacement therapy in males with primary hypogonadism or hypogonadotropic hypogonadism, plus carefully selected males with delayed puberty. The label says safety and effectiveness for age-related hypogonadism have not been established. ^[12]

The relevant fact here is narrower: menopause is not an approved indication, and the label itself does not establish insurance coverage for a woman receiving testosterone for menopausal symptoms.

Testosterone is a Schedule III controlled substance in the United States. Any legitimate route requires a prescription from a licensed clinician, an appropriate evaluation, and compliance with controlled-substance rules. Insurance coverage never changes that. ^[12]

The uncomfortable clarity: the approved pellet has a narrow label and narrow payer pathways. It is not the blanket exception a menopause clinic can point to when offering compounded estradiol or testosterone pellets.

There is no FDA-approved estradiol pellet in the policies we reviewed

Aetna, Blue Cross NC, and Capital Blue Cross each state that an FDA-approved commercially available estradiol pellet is not available in the United States. FDA's menopause-treatment pages list approved oral, transdermal, gel, spray, and vaginal forms — not a menopause estradiol implant. ^{[1][5][6][17]}

Most pellet programs marketed to women use compounded estradiol, testosterone, or a combination. The exact ingredients still matter: ask for them in writing. For the route-level tradeoffs, see our hormone pellets vs patch comparison.

“Bioidentical” is not an approval category

This trips up a lot of smart people.

Bioidentical describes a hormone's chemical relationship to a hormone the body makes. Compounded describes how a product was prepared and regulated. FDA-approved describes whether the finished drug passed FDA review for its labeled use. Those are three different questions.

FDA-approved estradiol and micronized progesterone products can be described as bioidentical. A custom-compounded pellet can also be marketed with that word. The word alone tells you nothing about approval or coverage. ^[14][17]

---

What codes can appear on a hormone-pellet claim?

CPT 11980 identifies subcutaneous implantation of hormone pellets. Effective January 1, 2026, J1073 identifies a 75 mg testosterone pellet and replaced legacy S0189 in the current payer policies reviewed. Compounded pellets may be submitted with unclassified drug codes such as J3490, J3590, or J7999; the clinic and payer must confirm the actual code. ^[2][3][4][7]

This is a real 2026 change, and it is easy to explain badly.

Claim element	Testopel	Compounded hormone pellet
Implantation procedure	CPT 11980 may be used	CPT 11980 may be used
Drug code through December 31, 2025	S0189 appeared in payer policies	No single universal compounded-pellet code
Drug code from January 1, 2026	J1073 — testosterone pellet, 75 mg	May be reported under an unclassified drug code such as J3490, J3590, or J7999, depending on payer and claim
What the code proves	It identifies the product or service submitted	It identifies how the claim was submitted
What the code does not prove	Coverage, medical necessity, network status, or payment	FDA approval, coverage, medical necessity, network status, or payment

A code is a label, not a benefit.

Four coding rules that save trouble

1. 1. Get the codes from the clinic. Do not tell a clinic which diagnosis to use.
2. 2. Ask whether the drug and procedure are submitted separately. A plan can deny one and process the other.
3. 3. Ask whether the product is Testopel or compounded. J1073 should not be used as a generic synonym for every testosterone pellet.
4. 4. Do not treat an NDC or other identifier as FDA approval. Product identification and approval status are different questions.

---

Why are many hormone-pellet clinics cash-only?

Some pellet practices stay outside insurance by design: they collect payment at the visit, provide an itemized document, and leave any patient-submitted claim or reimbursement request to the patient. A public 18-page female pellet intake packet shows how that structure can work — and why you need to read every form before signing. ^[18]

This matters because the packet puts the insurance disclaimer, reimbursement letter, and privacy restriction in one place.

The packet is hosted on a clinic website, contains blank “Your Logo” and “Doctor or Clinic Name” fields, includes a BioTE dosage page, and appears designed for local branding. We read all 18 pages. Treat it as a template in public circulation, not proof that every certified clinic uses it unchanged.

Document A: the insurance disclaimer

The packet tells the patient the clinic requires payment at the time of service, may provide paperwork for the patient to submit, and will not contact the insurer. Its blunt line is: “We will not call, write, pre-certify, appeal.” ^[18]

Document B: the letter asking for reimbursement

A few pages later, the packet includes a prewritten letter of necessity. It argues that pellets provide steadier levels than other routes and ends by asking the insurer to “honor her request for reimbursement.” ^[18]

Document C: the privacy restriction form

Near the end, the packet includes a HITECH-based request directing the practice not to disclose or bill the health plan for the fully paid service. The restricted item is prefilled as “subcutaneous pellet hormone replacement.” ^[18]

What these three documents mean together

The form	What it asks the patient or clinic to do	What you should ask
Insurance disclaimer	Pay in full and handle any insurer submission yourself	Will you give me an itemized bill, codes, records, and the refund policy?
Letter of necessity	Ask the insurer to reimburse	Who signs it, what evidence supports it, and does my denial reason make this argument relevant?
Restriction request	Keep the fully paid service out of health-plan payment or operations	Am I choosing this privacy restriction, and do I understand that I am accepting full financial responsibility?

One packet gives you a reimbursement letter, a clinic disclaimer saying it will not help with the insurer, and a form that can keep the service from being billed to the plan. Each document has a different job. The collision is that the patient can end up responsible for all three jobs at once.

Fairness matters more than a good line

Cash-only is not proof of fraud or bad care. Billing infrastructure is expensive, and a practice may choose not to contract with insurers. A patient may also choose privacy for a fully paid service.

The template contains one responsible detail worth crediting. It includes an explicit acknowledgment for a postmenopausal woman with a uterus receiving estradiol to take prescribed progesterone and names the uterine-lining risk of unopposed estrogen. ^[18]

We do not know which clinics use this template unchanged. We did not contact the host clinic, BioTE, or individual practices for comment. The evidence is the public packet itself — nothing more.

What a superbill actually is

A superbill is an itemized clinical and billing document that can support a patient-submitted out-of-network claim. It is not a reimbursement promise. Your benefits, exclusions, network, allowed amount, coding, and claim rules still decide whether money comes back.

It is still worth getting. You may need it for a claim, an HSA or FSA submission, a corrected bill, or an appeal. Just don't build a budget around it.

---

Does Medicare cover hormone pellets?

Original Medicare does not have a national blanket benefit for menopause hormone pellets. The active Palmetto documents reviewed for this page address low-testosterone treatment in males within that contractor's jurisdiction. They do not create a coverage path for compounded estradiol or testosterone pellets used for menopausal symptoms in women. Medicare Advantage plans add their own network, authorization, and evidence-of-coverage rules. ^[10][11]

Why older Medicare articles can mislead you

Some pages still cite CMS Article A55057 and LCD L36569. Both were retired in October 2025, so they cannot be treated as the current rule in August 2026. The active documents we could verify were Palmetto LCD L39086 and Article A58828; another Medicare contractor can use different active coverage material. ^[19][10][11]

That changes the language from “Medicare has one rule” to the accurate answer: your Medicare contractor or Medicare Advantage plan controls.

What to ask if you have Original Medicare

• Which Medicare Administrative Contractor applies where the service will be performed?
• Is there an active LCD or billing article for this exact product and diagnosis?
• Is CPT 11980 payable with this product and diagnosis?
• Is the product separately payable?
• Does the clinician accept Medicare assignment?
• What written pre-service notice will I receive if the clinician expects denial?

What to ask if you have Medicare Advantage

• Is the clinician and facility in-network?
• Does the plan require prior authorization?
• What does the plan's Evidence of Coverage say about compounded drugs, hormone implants, and out-of-network services?
• Does the plan follow an Original Medicare LCD, a separate commercial medical policy, or both?

One number we will not publish: a national Medicare pellet-coverage rate. We found no representative dataset that supports one.

For the broader question, see our Medicare and HRT guide.

---

Does Medicaid cover hormone pellets?

Medicaid coverage is state- and plan-specific. A 2026 Humana Florida Medicaid prior-authorization list includes Testopel under J1073, but the same document says authorization does not guarantee payment. A drug appearing on a PA list is not evidence that compounded menopause pellets are covered. ^[9]

That distinction catches people because “on the authorization list” sounds like “covered.” It isn't.

Five decisions sit between a PA-list entry and a paid claim:

1. 1. The exact product appears in the plan's rules.
2. 2. The member meets the clinical criteria.
3. 3. The product and service are covered benefits for that indication.
4. 4. The clinician, facility, and pharmacy or supplier meet the plan's requirements.
5. 5. The claim is submitted and adjudicated correctly.

Skipping any one can still produce a bill.

If you have Medicaid, start with your state program and, when applicable, your managed-care plan. Ask about the exact product, diagnosis, provider enrollment, site of service, authorization, and whether the insertion is evaluated separately.

---

Can I use an HSA or FSA for hormone pellets?

Potentially — but “usually yes” is too confident. HSA and health FSA reimbursement follows qualified-medical-expense rules, not the insurer's medical-policy decision. A prescribed treatment for a diagnosed condition may qualify when it is not reimbursed elsewhere, but the IRS does not publish a pellet-specific ruling and an FSA administrator can require documentation. Confirm before relying on reimbursement. ^[20]

Why an insurance denial does not decide the tax question

These are different rulebooks:

• Your health plan decides whether it will pay a claim.
• Federal tax rules decide whether an HSA distribution or FSA reimbursement is for a qualified medical expense.
• Your FSA administrator applies the plan's substantiation requirements.

A plan denial does not automatically make an expense HSA- or FSA-eligible. It also does not automatically disqualify it.

What to keep

• The prescription or clinician order
• An itemized receipt with the date, provider, service, and amount
• The product and procedure description
• Proof of what insurance did or did not reimburse
• Any letter of medical necessity the administrator specifically requests

What to ask the administrator

• Is this exact prescribed treatment eligible under my plan?
• Do you treat the pellet product and insertion as separate expenses?
• Is a letter of medical necessity required?
• What information must the itemized receipt contain?
• What happens if the claim is rejected?

HSA or FSA money does not lower the sticker price. It can lower the after-tax cost when the expense qualifies. Do not let a clinic round that up into “insurance coverage.”

→ Not sure whether pellets, an FDA-approved route, or in-person care fits your situation? Use Find My HRT Path.

---

What do hormone pellets cost without insurance?

In our August 27, 2026 check of four clinic pages with public prices, women's insertion prices ranged from $300 to $500. The pages described repeat treatment every three to four months, and one listed a separate $160 initial consult and lab panel. The resulting public examples ran from about $1,095 to $2,400 when frequency and stated extras were included — not a national average. ^{[21][22][23][24]}

An advertised insertion price is not an annual treatment cost. That is why we built this dated price check instead of repeating a floating “typical” number.

Public clinic-price audit

Clinic page checked	Published women's price	Published timing or extras	What the annual math shows
Women's Wellness Now	$365	Every 3–4 months	$1,095–$1,460 for 3–4 insertions, before any unlisted extras. [23]
Robinson Wellness	$410 per procedure	Most women return every 3–4 months	Straight multiplication is $1,230–$1,640; the clinic page separately states about $1,500–$1,800 annually. Ask what additional care explains the difference. [22]
Highland Longevity	$300–$500 per insertion	Every 3–4 months; page lists $100–$400 in possible additional costs	The page states $1,200–$2,000 annually, or up to $2,400 when its maximum additional-cost figure is added. [21]
Cherry Heights Family Clinic	About $400 per women's session	$160 initial consultation and lab panel	$1,360–$1,760 for the initial charge plus 3–4 sessions, before other follow-up. [24]

What this price audit proves — and what it doesn't

It proves that public clinic prices vary, package contents vary, and annual cost cannot be inferred from one insertion number.

It does not establish a national average. The four pages are a transparent convenience sample, not a representative survey of every clinic, state, dose, or brand. For broader route-by-route spending, see our 2026 HRT cost guide.

Build your own first-year number

Cost component	Clinic quote	Included in package?	Times in year one	Annual amount
Initial consultation
Baseline labs
Pellet product
Insertion
Follow-up visit
Monitoring labs
Repeat insertions
Membership or administration fee
Potential removal fee
Estimated year one

Ask about the deposit separately:

• Is it refundable?
• Until what date?
• What happens if you change your mind after labs but before insertion?
• What happens if the insurer denies the visit, laboratory work, procedure, or product?
• Does the quote include removal or treatment of an implant-site problem?

---

My hormone-pellet claim was denied. Should I appeal?

Read the denial reason before you appeal. A coding mistake, missing authorization, wrong product, network problem, or medical-necessity decision can support a correction or review. An explicit benefit exclusion is harder because the contract — not the completeness of your medical records — may be the issue.

Decode the denial first

What the letter says	What it usually means	What to do next
Excluded benefit	The contract says the plan does not pay for this category	Request the exact exclusion language and confirm it was applied to the correct product and claim.
Experimental or investigational	The plan says the evidence does not meet its policy standard	Request the medical policy by name and number; ask about internal and external review.
Not medically necessary	Submitted records did not satisfy stated criteria	Ask which criterion failed and what records were reviewed.
No prior authorization	Required approval was not obtained or linked to the claim	Ask whether the provider can correct the authorization or whether retrospective review is allowed.
Out-of-network	The clinician, facility, or laboratory is outside the contracted network	Ask for the allowed amount and your out-of-network benefit.
Coding or claim error	Product, diagnosis, units, modifier, authorization, or place of service may be wrong	Ask the billing office to review the submitted claim and file a corrected claim when appropriate.

The first two checks are cheaper than an appeal

One: ask the billing office to inspect the claim. A corrected claim is faster than an appeal when the problem is a wrong code, missing authorization number, wrong units, or incorrect provider information.

Two: read the actual benefit and medical-policy language. A PPO with out-of-network benefits and no applicable pellet exclusion is different from a plan that expressly excludes the treatment. Do not spend weeks proving medical necessity when the denial is contractual.

Internal and external review timelines

Federal consumer guidance generally gives at least 180 days from a denial to request an internal appeal. It describes decision periods of up to 30 days for a pre-service claim and 60 days for a post-service claim, with expedited review for qualifying urgent cases. External review may be available after internal review for certain medical-judgment or experimental-treatment denials, generally subject to a four-month request window. Your plan and state rules control the exact process. (HealthCare.gov: internal appeals; external review)

External review is not available for every contractual exclusion.

The clinic-help question matters before treatment

The public pellet packet we audited says the clinic will not pre-certify, appeal, or contact the insurer. That is a template, not proof of what your clinic does. Ask your clinic now whether it will provide records, a claim correction, an authorization response, or clinical support for an appeal. ^[18]

Keep:

• The denial letter
• The Explanation of Benefits
• The itemized bill or superbill
• The current medical policy
• Authorization records
• Clinical records relevant to the request
• Names, dates, reference numbers, and notes from every call

---

What should I say when I call my insurance company?

Ask about the exact pellet and each of the five claim components separately. Record the representative's name, date, reference number, policy used, and whether the answer is general benefit information, a pre-service estimate, prior authorization, or a formal coverage determination.

Read this out loud:

“I'm considering an implanted hormone product and need to check coverage before treatment.

The product is [exact product]. It contains [ingredient]. It is [compounded / Testopel / I don't know yet]. My provider expects to submit CPT [code], HCPCS or drug code [code], and diagnosis code [provided by the clinic].

Can you check these separately: the consultation, laboratory work, pellet product, implantation procedure, and follow-up or removal?

Is this exact product a covered benefit for that diagnosis? Is it excluded, considered investigational, or subject to medical-necessity criteria? Is prior authorization required? Are the clinician, facility, and laboratory in-network?

Which policy did you use, what is its effective date, and may I have a reference number or written response?”

Then ask:

• Did you check my exact plan or a general medical policy?
• Is the pellet processed under the medical benefit, pharmacy benefit, or neither?
• Is CPT 11980 payable with this exact product and diagnosis?
• Are the drug and procedure authorized separately?
• Are there quantity or frequency limits?
• What is the allowed amount and my estimated share?
• Does my deductible apply?
• Would medically necessary removal or implant-site care be handled separately?
• What are my internal and external appeal rights if the claim is denied?

Write down: date and time, representative, reference number, plan name, policy name and effective date, product checked, codes checked, and the answer for each of the five components.

A verbal benefits quote is useful. It is not the same as a guarantee of payment. Humana's own Medicaid authorization list says that plainly. ^[9]

---

Does a state menopause-coverage law make pellets covered?

No state law reviewed for this page creates a blanket guarantee for compounded menopause pellets. Recent laws can expand access to medically necessary menopause treatment or make already-covered hormone prescriptions easier to fill, but the exact products, plan types, FDA status, medical-policy exclusions, and effective dates still matter.

The laws are not interchangeable. A route list also cannot be read as an automatic pellet exclusion when the statute itself says “including, but not limited to.”

Four current examples

State	What the current law does	What it means for pellets
Illinois	Public Act 103-0703 took effect January 1, 2026 and requires specified plans and Medicaid coverage for medically necessary menopause hormone therapy, including FDA-approved modalities such as oral, transdermal, topical, and vaginal-ring routes. The phrase is “including, but not limited to,” so the route list is not exhaustive.	The law strengthens coverage for qualifying menopause treatment. It does not turn a compounded pellet into an FDA-approved product or erase a plan's applicable medical-policy analysis. [25]
New Jersey	Public Law 2025, Chapter 200 establishes coverage requirements for medically necessary perimenopause and menopause services under specified health-benefit arrangements.	It is a menopause-care mandate, not a public guarantee that every compounded pellet or cash-only clinic is covered. [26]
Oregon	Enrolled HB 3064 was signed and requires specified health plans to cover treatment of perimenopause, menopause, and postmenopause for covered plans beginning in 2026.	Product, network, plan scope, and medical-policy rules still control. The law does not name compounded pellets as an automatic benefit. [27]
Washington	RCW 48.43.845 applies to plans issued or renewed on or after January 1, 2026 that already cover prescription hormone therapy and requires reimbursement for a 12-month refill in qualifying situations; controlled substances are excluded from that refill rule.	This improves supply access for already-covered prescriptions. It is not a first-dollar mandate for pellets, and the controlled-substance exception matters for testosterone. [28]

Ask whether your plan is subject to the state mandate, when the provision took effect for your plan year, and whether the exact product is covered. Do not assume that a law applying to one plan type governs every employer or public plan.

---

What hormone therapy might insurance cover instead?

FDA approval does not guarantee formulary coverage, but named FDA-approved products have standard medical or pharmacy-benefit pathways that a compounded pellet often lacks. Your plan can still impose tiers, prior authorization, step therapy, quantity limits, network rules, or exclusions. The useful comparison is your exact formulary — not a promise that every patch or pill is cheap. ^[17][29]

Here is one current, reproducible example. The 2026 Harvard Pilgrim Core Rhode Island five-tier formulary, administered through Optum Rx and updated August 15, 2026, placed several menopause-related generics on named tiers:

Product in this one 2026 formulary	Route	Tier shown
Generic estradiol	Oral tablet	1
Generic estradiol	Twice-weekly or weekly transdermal patch	2
Generic estradiol	Vaginal cream or tablet	2
Generic micronized progesterone	Oral capsule	2
Generic estradiol	Transdermal gel	3
Estring	Vaginal ring	3
Premarin	Oral tablet or vaginal cream	3

That is one plan, not a national tier table. Its value is the contrast: the plan names products, routes, strengths, and tiers, while the compounded-pellet policies treat the implanted product through medical-policy and unclassified-drug pathways. Your formulary may look different. ^[30]

Questions to ask about an FDA-approved alternative

• Is the exact generic or brand on my current formulary?
• Which tier?
• Is prior authorization, step therapy, or a quantity limit attached?
• Does my deductible apply before the tier copay?
• Must I use a preferred pharmacy or mail order?
• Is the prescribed route systemic or local, and is that route appropriate for the symptoms being treated?
• If I have a uterus and systemic estrogen is being considered, what is the clinician's uterine-protection plan?

This is not permission to swap treatments on your own. It is permission to ask for a route-neutral comparison before you pay for an implanted dose.

Finding a menopause clinician who bills commercial insurance

Midi Health's real advantage for this reader is not that it “beats” every pellet clinic. It is that its model includes insurance-billed menopause care and FDA-approved medication options. Midi says it is available in all 50 states and works with many commercial plans, but participation varies by state and exact plan. It does not accept Medicaid or Medi-Cal and cannot treat those members even on a self-pay basis; Medicare coverage is not a blanket yes, so beneficiaries should verify their plan or the available self-pay path. ^[31]

Midi's published self-pay prices are $250 for an initial visit and $150 for follow-ups, with prescriptions and outside laboratory charges separate. Confirm current benefits and charges before booking. ^[31]

→ Check whether Midi accepts your insurance and is available for your plan Verify the visit and the prescription separately. An in-network consult does not guarantee that every medication is on your formulary.

---

If I'm paying cash anyway, what is the honest comparison?

Compare the full cash model against the full pellet quote — not a first-month teaser against a first-year procedure total. The right columns are regulatory category, visit cost, medication cost, laboratory cost, repeat frequency, dose flexibility, and what happens if the first plan is not a fit.

Some women read every policy above and still decide they do not want to fight insurance. That's a completely reasonable place to land. The answer just needs to remain honest.

Cash-pay path	Published price checked in August 2026	Regulatory category	Insurance handling	What to verify before paying
Compounded pellet clinic	Four-clinic postings: $300–$500 per women's insertion, with 3–4 month schedules and separate extras on some pages	Usually compounded estradiol and/or testosterone; exact product must be named	Commonly cash-pay; plan treatment varies	Ingredients, compounder, full annual quote, monitoring, removal, refund terms
Winona compounded cream plan	$89/month on the current public pricing page	Compounded	Winona says it does not accept insurance	Exact prescribed ingredients, what is included, renewal price, and current checkout total
Winona FDA-approved estradiol patch plan	$149/month on the current public pricing page	FDA-approved prescription product	Cash-pay program; no insurance billing by Winona	Whether patch alone fits the clinical plan, any separate progesterone or other medication, and total checkout price
Sesame menopause program	Public page lists $59/month	Care model; medication category depends on prescription	Sesame visits are cash-pay; a retail pharmacy may process a prescription through insurance	Included visits or messaging, lab terms, pharmacy cost, formulary, and state availability

Winona offers FDA-approved and compounded options. Those are different regulatory categories. We will not tell you they are equivalent, or that compounded is safer, more natural, or better. Ask which category your exact prescription falls into before you pay. Winona's prices and program terms can change, so confirm them at checkout. ^[32]

→ Compare Winona's current monthly options with the annual pellet quote in your hand Compare twelve months, every required medication, labs, and follow-up — not only the first charge.

---

How can I get another opinion if my clinician only offers pellets?

A second opinion is reasonable when the only clinician who took your symptoms seriously also sells one delivery system. You do not have to dismiss that clinician or commit to a membership to ask another prescriber to compare FDA-approved, compounded, local, systemic, and nonhormonal options for your situation.

Sesame's menopause care is cash-pay rather than insurance-billed. Its current program page lists $59 per month and says laboratory work ordered through the program is included; prescriptions are separate, and a pharmacy may be able to process an eligible prescription through your insurance. Verify the current program, clinician, state, laboratory terms, and medication cost before booking. ^[33]

The limit, first: Sesame does not turn the visit into an insured visit. Treat it as access to a clinician, not proof of coverage.

→ See Sesame's current menopause-care price and appointment availability

---

What did The HRT Index actually verify?

We think you should be able to check our work. This page separates what we opened from what remains plan-specific, keeps FDA-approved and compounded products in different categories, and dates every commercial fact used.

Public coverage documents checked

• Aetna CPB 0345
• UnitedHealthcare's 2026 testosterone replacement policy
• Cigna IP0251 and IP0351
• Blue Cross NC's menopause-pellet policy
• Capital Blue Cross Medical Policy 2.345
• Arkansas Blue Cross and Blue Shield's hormone-pellet policy
• Blue Cross & Blue Shield of Mississippi's hormone-pellet policy for women
• Humana Florida Medicaid's 2026 provider-administered drug PA list
• Active Palmetto Medicare LCD L39086 and billing article A58828

Other primary or direct sources checked

• Current Testopel label and controlled-substance status
• FDA guidance on menopause therapies and compounded hormones
• ACOG guidance on compounded menopausal hormone therapy and testosterone pellets
• The Menopause Society's explanation of FDA-approved versus compounded bioidentical hormones
• Four public clinic-price pages
• One current plan formulary updated August 15, 2026
• The 18-page public pellet intake packet
• Current insurer appeal guidance and IRS qualified-medical-expense guidance
• Current Illinois, New Jersey, Oregon, and Washington law text or official legislative records
• Midi, Winona, and Sesame's current public insurance, availability, and pricing pages

What we did not verify

• Your member contract or current eligibility
• Your exact claim, diagnosis, or authorization
• The quality of any individual pellet clinic
• Whether the public intake template is used unchanged by a particular practice
• A representative national pellet-denial rate
• A representative national pellet price
• How often a patient-submitted out-of-network claim receives partial reimbursement
• A pellet-specific IRS ruling
• Whether a posted clinic or provider price will remain unchanged at checkout

How this page was made

This page follows The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly.

When we compare providers, we use five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not assign invented numeric scores.

This is editorial research. It is not medically reviewed by a clinician, and nothing here is medical advice. Decisions about hormone therapy belong to you and a licensed clinician who knows your history.

Corrections: if a policy, price, formulary, or provider term has changed, contact us. We will correct the page and date the change.

---

What are women actually asking before they pay?

The emotional trigger is not abstract insurance policy. It is being asked for money before anyone has explained which part of the treatment is excluded. One woman described it this way in a menopause forum:

“I was told that I have to pay up front for the HRT because it's not covered by insurance.”

— Xina123, r/Menopause (source)

This is included as voice-of-customer evidence about the confusion behind the query — not as evidence that a plan covers or denies anything.

That sentence is why the five-part breakdown matters. “HRT isn't covered” can mean the clinic is cash-only, the compounded product is excluded, the procedure is excluded, the clinician is out-of-network, the deductible is high, or nobody checked the exact plan.

---

Frequently asked questions about hormone pellet insurance coverage

Does insurance cover hormone pellets for menopause?

Usually not when the product is a compounded estradiol, testosterone, progesterone, or combination pellet. Every commercial policy in this review that directly addressed compounded menopause pellets excluded or restricted them; the separate Testopel policies described only narrow, diagnosis-specific paths. Your visit, outside labs, or another FDA-approved prescription may be evaluated separately, and your member contract controls. ^{[1][2][3][4][5][6][7][8]}

Does Aetna cover hormone pellets?

Aetna's CPB 0345, last reviewed July 8, 2026, treats implantable estradiol as experimental, investigational, or unproven and lists menopause-related testosterone-pellet use among noncovered indications. Testopel has narrow criteria for specified non-menopause indications. Aetna's progesterone-pellet language is indication-specific, so do not turn it into a blanket statement about every progesterone use. ^[1]

Does Blue Cross Blue Shield cover hormone pellets?

There is no single national Blue Cross policy. The North Carolina, Capital, Arkansas, and Mississippi documents reviewed all restricted or excluded relevant menopause-pellet uses, but the Blue plan named on your card and your member contract control. ^[5][6][7][8]

Does Cigna cover hormone pellets?

Cigna separates compounded pellets from Testopel. IP0251 classifies compounded hormone pellets as experimental, investigational, or unproven; IP0351 provides narrow criteria for the FDA-approved testosterone implant. That split is the whole coverage question in miniature. ^[3][4]

Does UnitedHealthcare cover hormone pellets?

UnitedHealthcare's 2026 commercial policy says compounded testosterone, estrogen, and progesterone pellets are not proven or medically necessary for any indication under that policy. Testopel has separate diagnosis-specific criteria, and a code or authorization still does not guarantee payment. ^[2]

Does Medicare cover hormone pellets for women?

The active Medicare documents reviewed do not create a national menopause-pellet pathway for women. The Palmetto LCD and article concern low-testosterone treatment in males within that contractor's jurisdiction. Medicare Advantage adds plan-specific network and authorization rules. ^[10][11]

Does Medicaid cover hormone pellets?

It depends on the state and managed-care plan. Testopel/J1073 appears on Humana Florida Medicaid's 2026 prior-authorization list, but the document says authorization does not guarantee payment and does not establish coverage for compounded menopause pellets. ^[9]

Is Biote covered by insurance?

Biote-affiliated clinics use custom-compounded pellets, and those products fall into the compounded-pellet category addressed by the commercial policies reviewed. The visit, labs, clinic network, and patient-submitted claim must still be checked separately. See our independent Biote review for the product, clinic, and price questions that matter. ^[34]

Is SottoPelle covered by insurance?

SottoPelle is a clinician method or system, not an insurance benefit category. Ask which exact compounded product and pharmacy the clinician will use, then check that product, CPT 11980, network, and diagnosis against your plan. See our SottoPelle vs Biote comparison. ^[35]

Are hormone pellets FDA-approved?

Testopel is an FDA-approved 75 mg testosterone pellet with male labeled indications. There is no FDA-approved estradiol pellet identified in the current payer and FDA sources reviewed, and compounded menopause pellets are not FDA-approved finished drugs. ^[12][1][17]

Is Testopel covered by insurance?

Sometimes, when the product, diagnosis, patient criteria, documentation, authorization, and plan all match. The policies reviewed describe narrow paths for qualifying testosterone indications and, in some plans, gender-affirming care. Testopel is not FDA-approved for menopausal symptoms, and it is a Schedule III controlled substance that requires a prescription. ^[12][1][4]

Can I use an HSA or FSA for hormone pellets?

Possibly. The expense must meet qualified-medical-expense rules, remain unreimbursed, and satisfy the HSA or FSA documentation requirements. There is no pellet-specific IRS ruling, so confirm with the administrator before relying on reimbursement. ^[20]

What is CPT 11980?

It is the procedure code associated with subcutaneous implantation of hormone pellets. A valid code identifies the submitted service; it does not establish coverage for the product, diagnosis, clinician, facility, or plan. ^[1][3][4]

What is HCPCS J1073?

J1073 identifies a 75 mg testosterone pellet and became effective January 1, 2026 in the payer policies reviewed. Those policies removed legacy S0189 at the end of 2025. J1073 is product identification, not a payment guarantee. ^[2][4][7]

How are compounded pellets coded?

There is no single universal answer. Cigna's compounded-medication policy names unclassified drug codes including J3490, J3590, and J7999; the exact code depends on the product, clinic, and payer. Ask for the code before treatment. ^[3]

Will a letter of medical necessity make insurance pay?

Not when the contract expressly excludes the service. A letter can matter when the dispute is medical necessity, missing evidence, or an incorrect application of policy. It cannot create a benefit the contract does not contain.

Does a superbill guarantee reimbursement?

No. It is an itemized document that can support a patient-submitted claim. Reimbursement still depends on out-of-network benefits, exclusions, allowed amount, coding, and claim rules.

Does prior authorization guarantee payment?

No. It means a request passed a defined review at a defined time. Eligibility, network, benefit exclusions, coding, and final claim adjudication still apply. Humana's current Florida Medicaid list states that authorization does not guarantee payment. ^[9]

Will insurance cover pellet removal?

It depends on why removal is needed, who performs it, where it happens, and what the plan says. Ask before insertion whether removal and implant-site care are included in the clinic package or billed separately. Testopel's label says removal may be needed when treatment must be discontinued. ^[12]

How much do hormone pellets cost without insurance?

The four public clinic pages checked listed women's insertion prices from $300 to $500, generally on three- to four-month schedules. The public examples produced roughly $1,095 to $2,400 when stated frequency and extras were included. That is a transparent four-clinic audit, not a national average. ^{[21][22][23][24]}

Can I appeal a hormone-pellet denial?

Yes, but match the appeal to the denial reason. Coding, authorization, network, or medical-necessity errors may be correctable; a contractual exclusion is harder. Federal guidance generally gives at least 180 days for an internal appeal, with external review available for some medical-judgment or experimental-treatment denials. (HealthCare.gov: internal appeals; external review)

Does my state's menopause law cover pellets?

No state law reviewed creates a blanket compounded-pellet benefit. Illinois, New Jersey, and Oregon expanded menopause-treatment coverage for specified plans; Washington's law concerns longer fills of already-covered hormone prescriptions and excludes controlled substances from that refill rule. Exact plan scope still matters. ^{[25][26][27][28]}

What menopause hormone therapy might my insurance cover?

Check your exact formulary. In one current 2026 Harvard Pilgrim Rhode Island formulary, oral estradiol was Tier 1; estradiol patches, vaginal estradiol, and oral progesterone were Tier 2; estradiol gel, Estring, and Premarin products were Tier 3. Your plan may differ. ^[30]

---

Where this leaves you

You came here to find out whether insurance covers hormone pellets. For a compounded pellet used for menopause, the answer is usually no — and now you know exactly what that answer does and does not include.

If you're still considering pellets: get the product, ingredients, compounder, codes, full first-year quote, follow-up, removal terms, and refund policy in writing before any deposit. You're allowed to choose this. Just choose it knowing what it is.

If insurance matters more than you realized: ask for a route-neutral comparison of the named FDA-approved products on your formulary. The covered path may be a patch, pill, gel, spray, ring, or vaginal product, but the right route depends on your symptoms and history.

If you received a denial: read the reason first. A corrected claim, authorization problem, medical-policy appeal, and contractual exclusion are four different jobs.

If you're paying cash: compare twelve-month totals, every medication, labs, visits, and what happens if the first plan doesn't fit. Do not compare a monthly headline with an annual procedure bill.

And if you're honestly not sure what fits your symptoms, your risk history, your insurance, and your state: that is the most common place to be. It is not a failure to be there.

Still not sure which HRT program is right for you? Take our free Find My HRT Path matching quiz.

Find My HRT Path collects sensitive health information and is handled under our consumer health data and privacy policy.

---

The HRT Index is reader-supported. Some links to Midi, Winona, and Sesame are affiliate links, and we may earn a commission if you use them. We have no affiliate relationship with the pellet brands or payer policies analyzed on this page. See our affiliate disclosure.

---

Sources

¹ Aetna, Clinical Policy Bulletin 0345: Implantable Hormone Pellets, last reviewed July 8, 2026.

² UnitedHealthcare, Testosterone Replacement or Supplementation Therapy, effective January 1, 2026.

³ Cigna, Coverage Policy IP0251, Compounded Medications, effective December 15, 2025.

⁴ Cigna, Coverage Policy IP0351, Testosterone Injectable and Implant, effective December 15, 2025.

⁵ Blue Cross NC, Hormone Pellet Implantation for Treatment of Menopause-Related Symptoms, maintained policy; update posted April 15, 2026.

⁶ Capital Blue Cross, Medical Policy 2.345, Implantable Hormone Pellets, effective January 1, 2026.

⁷ Arkansas Blue Cross and Blue Shield, medical policy 2009047, last reviewed October 2025.

⁸ Blue Cross & Blue Shield of Mississippi, Hormone Pellet Implantation for Hormone Replacement Therapy in Women, reviewed July 15, 2026.

⁹ Humana, 2026 Florida Medicaid Provider-Administered Drug Prior Authorization List, revised July 1, 2026.

¹⁰ CMS Medicare Coverage Database, LCD L39086: Treatment of Males with Low Testosterone.

¹¹ CMS Medicare Coverage Database, Article A58828: Billing and Coding—Treatment of Males with Low Testosterone, revision effective April 2, 2026.

¹² DailyMed, TESTOPEL—testosterone pellet label, current label accessed August 2026.

¹³ U.S. Food and Drug Administration, Menopause and compounded “bioidentical” hormone therapy, accessed August 2026.

¹⁴ The Menopause Society, patient education on hormone therapy and custom-compounded hormones, accessed August 2026.

¹⁵ Wender et al., Compounded hormonal pellets: a critical review of current evidence, 2025.

¹⁶ American College of Obstetricians and Gynecologists, Compounded Bioidentical Menopausal Hormone Therapy: Clinical Consensus No. 6, November 2023.

¹⁷ U.S. Food and Drug Administration, Hormone Replacement Therapies Can Help Women With Bothersome Menopausal Symptoms, accessed August 2026.

¹⁸ Keys Med Spa, Female New Patient Package, 18-page public PDF accessed August 27, 2026.

¹⁹ CMS Medicare Coverage Database, retired LCD L36569, retired October 2025.

²⁰ Internal Revenue Service, Publication 969: Health Savings Accounts and Other Tax-Favored Health Plans and Publication 502: Medical and Dental Expenses, current editions accessed August 2026.

²¹ Highland Longevity, Cost of Hormone Pellets: 2026 Pricing, accessed August 27, 2026.

²² Robinson Wellness, Cost of Biote Pellets for Women, price dated September 2025; accessed August 27, 2026.

²³ Women's Wellness Now, Bioidentical Hormone Pellet Therapy for Women, accessed August 27, 2026.

²⁴ Cherry Heights Family Clinic, Hormone Pellet Therapy, accessed August 27, 2026.

²⁵ Illinois General Assembly, Public Act 103-0703, effective January 1, 2026.

²⁶ New Jersey Legislature, Public Law 2025, Chapter 200.

²⁷ Oregon Legislative Information System, HB 3064, enrolled, governor-signed.

²⁸ Washington State Legislature, RCW 48.43.845, effective for qualifying plans issued or renewed on or after January 1, 2026.

²⁹ Optum Rx, formulary guidance explaining that the member benefit document controls and formularies can change, accessed August 2026.

³⁰ Harvard Pilgrim Health Care/Optum Rx, Core Rhode Island 5-Tier 2026 Prescription Drug List, updated August 15, 2026.

³¹ Midi Health, current public insurance, availability, and pricing pages, accessed August 27, 2026.

³² Winona, current public pricing and insurance pages, accessed August 27, 2026.

³³ Sesame, current public menopause-care and insurance pages, accessed August 27, 2026.

³⁴ Biote, Hormone Pellet Therapy for Women, accessed August 2026.

³⁵ SottoPelle method descriptions and FAQs published by participating clinic HealthLink Medical Group, accessed August 2026.